Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties. It has been used in trials studying the prevention of Liver... The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury.
- Mechanism
- Curator reviewed · 2 references
Nafamostat mesilate inhibits various enzyme systems, such as coagulation and fibrinolytic systems (thrombin, Xa, and XIIa), the kallikrein–kinin system, the complement system, pancreatic proteases and activation of protease-activated receptors (PARs). Nafamostat inhibits lipopolysaccharide-induced nitric oxide production, apoptosis, and interleukin (IL)-6 and IL-8 levels in cultured human trophoblasts. It is shown to act as an antioxidant in TNF-α-induced ROS production.
- Primary indication
- Used as an anticoagulant in patients with disseminative blood vessel coagulation, hemorrhagic lesions, and hemorrhagic tendencies.Curator reviewed
- Formula / weight
- C19H17N5O2 · 347.378 g/mol (avg)
- Code names
- CKD-314
Resolves to
MQQNFDZXWVTQEH-UHFFFAOYSA-NSMILESNC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC2=C(C=C1)C=C(C=C2)C(N)=NWhat you can answer from here — as of September 21, 2026
Which drugs share a target with Nafamostat, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account